WO1997030035A1
(en)
|
1996-02-13 |
1997-08-21 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
DE69709319T2
(de)
|
1996-03-05 |
2002-08-14 |
Astrazeneca Ab |
4-anilinochinazolin derivate
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID23978A
(id)
|
1997-11-11 |
2000-06-14 |
Pfizer Prod Inc |
Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
EP1087970B1
(de)
|
1998-06-19 |
2004-04-28 |
Pfizer Products Inc. |
Pyrrolo(2,3-d)pyrimidin-verbindungen
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
NZ510580A
(en)
|
1998-09-29 |
2003-03-28 |
American Cyanamid Co |
Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
PL201475B1
(pl)
*
|
1998-09-29 |
2009-04-30 |
Wyeth Corp |
Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
ES2295035T3
(es)
|
1999-07-09 |
2008-04-16 |
Glaxo Group Limited |
Anilinoquinazolinas como inhibidores de proteina tirosina quinasa.
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
PT1676845E
(pt)
|
1999-11-05 |
2008-08-05 |
Astrazeneca Ab |
Novos derivados de quinazolina
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
EP1382339B1
(de)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Pyrrolo¬2,3-d pyrimidinderivate enthaltende Zusammensetzungen
|
AR029423A1
(es)
|
1999-12-21 |
2003-06-25 |
Sugen Inc |
Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
|
CN100351253C
(zh)
|
2000-06-26 |
2007-11-28 |
辉瑞产品公司 |
作为免疫抑制剂的吡咯并[2,3-d]嘧啶化合物
|
CN1211382C
(zh)
*
|
2000-06-30 |
2005-07-20 |
葛兰素集团有限公司 |
喹唑啉二甲苯磺酸盐化合物
|
AU2001289749B9
(en)
*
|
2000-07-26 |
2004-08-19 |
Smithkline Beecham P.L.C. |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
|
AU7993801A
(en)
*
|
2000-08-09 |
2002-02-18 |
Astrazeneca Ab |
Chemical compounds
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
AU2001295986B2
(en)
|
2000-10-20 |
2006-08-17 |
Eisai R&D Management Co., Ltd |
Nitrogenous aromatic ring compounds
|
JP2004531217A
(ja)
|
2001-01-05 |
2004-10-14 |
ファイザー・インク |
インスリン様成長因子i受容体に対する抗体
|
DE60203260T2
(de)
*
|
2001-01-16 |
2006-02-02 |
Glaxo Group Ltd., Greenford |
Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
ATE330956T1
(de)
|
2001-04-13 |
2006-07-15 |
Pfizer Prod Inc |
Bizyklisch substituierte 4- aminopyridopyrimidinderivate
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
ES2305435T3
(es)
*
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
Inhibidores de la rho-quinasa.
|
MXPA04006882A
(es)
*
|
2002-01-17 |
2004-12-06 |
Neurogen Corp |
Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
|
CA2473510A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
US6943172B2
(en)
|
2002-01-23 |
2005-09-13 |
Bayer Pharmaceuticals Corporation |
Rho-kinase inhibitors
|
EP1470131A2
(de)
|
2002-01-29 |
2004-10-27 |
Glaxo Group Limited |
"aminopiperidinverbindugen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen "
|
AR038240A1
(es)
|
2002-01-29 |
2005-01-05 |
Glaxo Group Ltd |
Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
|
CA2478050A1
(en)
|
2002-03-01 |
2003-09-12 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
WO2003086467A1
(en)
*
|
2002-04-08 |
2003-10-23 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
EP1521747B1
(de)
|
2002-07-15 |
2018-09-05 |
Symphony Evolution, Inc. |
Modulatoren von rezeptor-typ-kinase und anwendungsverfahren
|
US20050239784A1
(en)
*
|
2002-07-15 |
2005-10-27 |
Lacrampe Jean F A |
3-Phenyl analogs of toxoflavine as kinase inhibitors
|
DE60313339T2
(de)
*
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
US7629347B2
(en)
*
|
2002-10-09 |
2009-12-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
FR2846657B1
(fr)
|
2002-11-05 |
2004-12-24 |
Servier Lab |
Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
AU2003291394B2
(en)
|
2002-11-20 |
2009-06-25 |
Array Biopharma, Inc |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
JP2006509000A
(ja)
|
2002-11-26 |
2006-03-16 |
ファイザー・プロダクツ・インク |
移植片拒絶反応の処置の方法
|
US20040156869A1
(en)
*
|
2002-12-13 |
2004-08-12 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues
|
AU2003286321A1
(en)
|
2002-12-19 |
2004-07-14 |
Pfizer Inc. |
2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
|
DK1625121T3
(da)
|
2002-12-20 |
2010-05-10 |
Pfizer Prod Inc |
Pyrimidinderivater til behandling af abnorm cellevækst
|
OA13151A
(en)
|
2003-02-26 |
2006-12-13 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors.
|
CA2525969A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
TW200510373A
(en)
*
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
US7008953B2
(en)
|
2003-07-30 |
2006-03-07 |
Agouron Pharmaceuticals, Inc. |
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
WO2005011607A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Smithkline Beecham Corporation |
Treatment of cancers expressing p95 erbb2
|
US20050038047A1
(en)
*
|
2003-08-14 |
2005-02-17 |
Edwards Paul John |
Azaquinazoline derivatives
|
JP2007504122A
(ja)
|
2003-08-29 |
2007-03-01 |
ファイザー・インク |
新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
|
EP1678173A2
(de)
*
|
2003-09-09 |
2006-07-12 |
Neurogen Corporation |
4-heterobicyclylaminosubstituierte chinazoline und analoga davon als capsaicin-antagonisten
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
ATE532782T1
(de)
|
2003-09-26 |
2011-11-15 |
Exelixis Inc |
C-met-modulatoren und anwendungsverfahren
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005051919A1
(en)
*
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
AP2006003619A0
(en)
|
2003-12-23 |
2006-06-30 |
Pfizer |
Novel quinoline derivatives
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
CN1972688B
(zh)
|
2004-05-06 |
2012-06-27 |
沃尼尔·朗伯有限责任公司 |
4-苯胺基-喹唑啉-6-基-酰胺类化合物
|
US20060286102A1
(en)
*
|
2004-05-14 |
2006-12-21 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
JP2008501696A
(ja)
*
|
2004-06-04 |
2008-01-24 |
アンフォラ ディスカバリー コーポレーション |
Atp利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用
|
EP2322217A3
(de)
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
|
ME01788B
(me)
|
2004-08-26 |
2011-02-28 |
Pfizer |
Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
US20080206231A1
(en)
*
|
2004-10-05 |
2008-08-28 |
Oregon Health And Science University |
Compositions and Methods for Treating Disease
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
GB0428475D0
(en)
*
|
2004-12-30 |
2005-02-02 |
4 Aza Bioscience Nv |
Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
AU2006261607A1
(en)
*
|
2005-06-24 |
2006-12-28 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
US7537762B2
(en)
|
2005-09-07 |
2009-05-26 |
Amgen Fremont, Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
US7910595B2
(en)
*
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
CA2633760A1
(en)
*
|
2005-12-21 |
2007-07-05 |
Abbott Laboratories |
Anti-viral compounds
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
EP2295432A1
(de)
*
|
2006-02-10 |
2011-03-16 |
TransTech Pharma Inc. |
Verfahren zur Herstellung von Aminobenzimidazolderivaten
|
US20090036429A1
(en)
*
|
2006-02-17 |
2009-02-05 |
Ohler Norman E |
Hydroxypiperidine Derivatives and Uses Thereof
|
EP2021338A1
(de)
|
2006-05-09 |
2009-02-11 |
Pfizer Products Inc. |
Cycloalkylaminosäurederivate und pharmazeutische zusammensetzung davon
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
KR100760148B1
(ko)
|
2006-07-19 |
2007-09-18 |
주식회사 엘지생활건강 |
알파-리포산을 안정화시킨 화장료 조성물
|
US8338435B2
(en)
*
|
2006-07-20 |
2012-12-25 |
Gilead Sciences, Inc. |
Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
WO2008067119A2
(en)
*
|
2006-11-27 |
2008-06-05 |
Smithkline Beecham Corporation |
Novel compounds
|
CA2672737A1
(en)
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
TW200840584A
(en)
*
|
2006-12-26 |
2008-10-16 |
Gilead Sciences Inc |
Pyrido(3,2-d)pyrimidines useful for treating viral infections
|
US8637531B2
(en)
*
|
2006-12-26 |
2014-01-28 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyridmidines useful for treating viral infections
|
WO2008077649A1
(en)
*
|
2006-12-26 |
2008-07-03 |
Gilead Sciences, Inc. |
Pyrido(3,2-d)pyrimidines useful for treating viral infectons
|
EP2121681B1
(de)
|
2007-01-11 |
2015-04-15 |
Critical Outcome Technologies, Inc. |
Verbindungen und verfahren zur behandlung von krebs
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
ES2465673T3
(es)
|
2007-04-16 |
2014-06-06 |
Hutchison Medipharma Enterprises Limited |
Derivados de pirimidina
|
EP2146779B1
(de)
|
2007-04-18 |
2016-08-10 |
Pfizer Products Inc. |
Sulfonylamid-derivate zur behandlung von abnormalem zellwachstum
|
EP2141994A4
(de)
*
|
2007-04-26 |
2011-05-18 |
Avalon Pharmaceuticals |
Mehrringverbindungen und ihre verwendungen
|
KR20120011093A
(ko)
*
|
2007-05-09 |
2012-02-06 |
화이자 인코포레이티드 |
치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도
|
PL2185574T3
(pl)
|
2007-09-07 |
2013-09-30 |
Agensys Inc |
Przeciwciała i powiązane cząsteczki, które wiążą się do białek 24P4C12
|
WO2009057139A2
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
WO2009079797A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8314107B2
(en)
*
|
2008-04-23 |
2012-11-20 |
Rigel Pharmaceuticals, Inc. |
Carboxamide compounds and methods for using the same
|
US7829574B2
(en)
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
WO2010002998A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Gilead Sciences, Inc. |
2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
|
CA2999321A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
ES2432414T3
(es)
*
|
2008-08-12 |
2013-12-03 |
Glaxosmithkline Llc |
Compuestos químicos
|
BRPI0917459B1
(pt)
|
2008-08-20 |
2017-09-12 |
Zoetis Services Llc |
N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
|
TW201008933A
(en)
*
|
2008-08-29 |
2010-03-01 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine compounds
|
TW201016703A
(en)
*
|
2008-09-26 |
2010-05-01 |
Takeda Pharmaceutical |
Prevention and treatment of cancer with LKB1 non-expression (deletion or mutation)
|
TW201016704A
(en)
*
|
2008-09-26 |
2010-05-01 |
Takeda Pharmaceutical |
Prevention and treatment of cancer with RAS gene mutation
|
CA2737597C
(en)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
CN101735200B
(zh)
*
|
2008-11-17 |
2013-01-02 |
岑均达 |
喹唑啉类化合物
|
EA019959B1
(ru)
|
2009-01-16 |
2014-07-30 |
Экселиксис, Инк. |
Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
|
US20100204221A1
(en)
|
2009-02-09 |
2010-08-12 |
Hariprasad Vankayalapati |
Pyrrolopyrimidinyl axl kinase inhibitors
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
EP2400990A2
(de)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
EP2401614A1
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010107968A1
(en)
|
2009-03-18 |
2010-09-23 |
Osi Pharmaceuticals, Inc. |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
BR112012000735A2
(pt)
|
2009-07-13 |
2016-11-16 |
Genentech Inc |
"métodos, kits e conjuntos de compostos"
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
US20110064670A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
MX2012002909A
(es)
|
2009-09-17 |
2012-04-19 |
Hoffmann La Roche |
Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
|
CN102695416B
(zh)
|
2009-10-29 |
2017-03-08 |
金纳斯克公司 |
激酶抑制剂
|
EP2510110A1
(de)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molekulare biomarker zur vorhersage der reaktion auf tyrosinkinaseinhibitoren bei lungenkrebs
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
KR20120127495A
(ko)
|
2010-02-12 |
2012-11-21 |
화이자 인코포레이티드 |
8-플루오로-2-{4-[(메틸아미노)메틸]페닐}-1,3,4,5-테트라하이드로-6h-아제피노[5,4,3-cd]인돌-6-온의 염 및 다형체
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011159835A1
(en)
|
2010-06-16 |
2011-12-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
MY162132A
(en)
*
|
2010-06-23 |
2017-05-31 |
Hanmi Science Co Ltd |
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
CN104965084B
(zh)
|
2010-07-19 |
2017-09-29 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
EP2630134B9
(de)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivate als modulatoren des smoothened rezeptors
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
TR201905909T4
(tr)
|
2011-04-19 |
2019-05-21 |
Pfizer |
Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
EP2714937B1
(de)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
|
JP6105578B2
(ja)
|
2011-07-21 |
2017-03-29 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
複素環式プロテインキナーゼ阻害剤
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
KR20140059246A
(ko)
|
2011-09-22 |
2014-05-15 |
화이자 인코포레이티드 |
피롤로피리미딘 및 퓨린 유도체
|
BR112014007569A2
(pt)
|
2011-09-30 |
2017-04-18 |
Genentech Inc |
marcadores de metilação diagnósticos fenótipo epitelial ou mesenquimal e a resposta ao inibidor da quinase de egfr em tumores ou células tumorais
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
EP2909181B1
(de)
|
2012-10-16 |
2017-08-09 |
Tolero Pharmaceuticals, Inc. |
Pkm2-modulatoren und verfahren zu deren verwendung
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
JP6255038B2
(ja)
|
2013-02-26 |
2017-12-27 |
トリアクト セラピューティクス,インク. |
癌治療
|
EP2970205B1
(de)
|
2013-03-14 |
2019-05-08 |
Tolero Pharmaceuticals, Inc. |
Jak2- und alk2-inhibitoren und verfahren zu deren verwendung
|
PL2970211T3
(pl)
*
|
2013-03-15 |
2018-01-31 |
Quanticel Pharmaceuticals Inc |
Inhibitory demetylazy histonowej
|
EP2976085A1
(de)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von chronischen lebererkrankungen im zusammenhang mit einer niedrigen hepcidinexpression
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
SG11201509278XA
(en)
|
2013-05-14 |
2015-12-30 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
AR096654A1
(es)
*
|
2013-06-20 |
2016-01-27 |
Ab Science |
Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
PT3126528T
(pt)
|
2014-04-04 |
2021-09-09 |
Crown Bioscience Inc Taicang |
Métodos para determinar a responsividade a inibidores de mek/erk
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
BR112016024513A2
(pt)
|
2014-04-30 |
2017-08-15 |
Pfizer |
derivados de di-heterociclo ligados à cicloalquila
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2925224T3
(es)
|
2014-07-31 |
2022-10-14 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
IL302218B1
(en)
|
2014-08-28 |
2024-06-01 |
Eisai R&D Man Co Ltd |
Methods for the production of lanvotinib and its derivatives in a high degree of purity
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
CA2969830A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
CA2982928A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
EP3288957A4
(de)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
Nukleosidanaloga zur behandlung von viren der flaviviidae-familie und krebs
|
BR112017024933A8
(pt)
|
2015-05-18 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Alvocidib produce com a bioavailabilidade aumentada
|
EP3311841B1
(de)
|
2015-06-16 |
2021-07-28 |
PRISM BioLab Co., Ltd. |
Antikrebsmittel
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
BR112018002427A8
(pt)
|
2015-08-03 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JP6619519B2
(ja)
|
2016-12-19 |
2019-12-11 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
プロファイリングペプチドおよび感受性プロファイリングのための方法
|
KR102592246B1
(ko)
|
2016-12-22 |
2023-10-23 |
암젠 인크 |
폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP4141005B1
(de)
|
2017-09-08 |
2024-04-03 |
Amgen Inc. |
Inhibitoren von kras g12c und verfahren zur verwendung davon
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
US11285156B2
(en)
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
|
US20200115389A1
(en)
|
2018-09-18 |
2020-04-16 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
BR112021006407A8
(pt)
|
2018-10-04 |
2022-12-06 |
Inst Nat Sante Rech Med |
uso de inibidores do egfr para ceratodermas
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(de)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
MA54543A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
US20220073504A1
(en)
|
2018-12-20 |
2022-03-10 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
EP3930845A1
(de)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclische heterocyclyl-verbindungen und ihre verwendung
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
MX2021011289A
(es)
|
2019-03-22 |
2021-11-03 |
Sumitomo Pharma Oncology Inc |
Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
EP4048671A1
(de)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidinderivate als kras-sg12c- und kras-g12d-inhibitoren zur behandlung von krebs
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
KR20220109407A
(ko)
|
2019-11-04 |
2022-08-04 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
JP2023500328A
(ja)
|
2019-11-08 |
2023-01-05 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
EP4058432A1
(de)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Verbesserte synthese einer kras-g12c-hemmenden verbindung
|
WO2021097212A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
EP4065231A1
(de)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
IL294484A
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines Inc |
Dosage for shp2 inhibitor and methods for treating cancer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
CA3183032A1
(en)
|
2020-06-18 |
2021-12-23 |
Mallika Singh |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4267250A1
(de)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1-inhibitoren und verwendungen davon
|
CN117616031A
(zh)
|
2021-05-05 |
2024-02-27 |
锐新医药公司 |
用于治疗癌症的ras抑制剂
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
IL308193A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|